Erythropoietin and hypertension;Erythropoietin und arterielle hypertonie

Nieren- und Hochdruckkrankheiten

Volumn 28, Issue SUPPL. 1, 1999, Pages

  Luft, F C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cardiac function; Erythropoietin; Hemodialysis; Hypertension; Renal anemia

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CONFERENCE PAPER; DIALYSIS; HEART FUNCTION; HEART HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOGENESIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033067813     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Abraham P.A., M.G. Macres: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J. Am. Soc. Nephrol. 2, 927-936 (1991).
2. Austrian Multicenter Study Group of rhEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61, 399-403 (1992).
3. Berglund B., B. Ekblom: Effect of recombinant human erythropoietin treatment on blood pressure and some hematological parameters in healthy men. J. Intern. Med. 229, 125-130 (1991).
4. Bode-Böger S.M., R.H. Böger, M. Kuhn, J. Rademacher, J.C. Fröhlich: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50, 1255-1261 (1996).
5. Brunkhorst R., B. Nonnast-Daniel, K.M. Koch, U. Frei: Hypertension as a possible complication of recombinant human erythropoietin therapy. Contrib. Nephrol. 88, 118-125 (1991).
6. Canadian Erythropoietin Study Group: Association between recombinant erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br. Med. J. 300, 573-578 (1990).
7. Collins A.J., W.F. Keane: Higher hematocrit levels: do they improve patient outcomes, and are they cost effective? Nephrol. Dial. Transplant. 13, 1627-1629 (1998).
8. Cowgill L.D., K.M. James, J.K. Levy, A. Miller, R.T. Lobingier, J.C. Egrie: Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J. Am. Vet. Med. Assoc. 212, 521-528 (1998).
9. Delanty N., C. Vaugham, S. Frucht, P. Stubgen: Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 49, 686-689 (1997).
10. Edmunds M.E., J. Walls, B. Tucker, L.R. Baker, C.R. Tomson, M. Ward, J. Cunningham, R. Moore, C.G. Winearls: Seizures in hemodialysis patients treated with recombinant human erythropoietin. Nephrol. Dial. Transplant. 4, 1065-1069 (1989).
11. Eschbach J.W., M.H. Abdulhadi, J.K. Browne, B.G. Delano, M.R. Downing, J.C. Egrie, R.W. Evans, E.A. Friedman, S.E. Graber, N.R. Haley: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000 (1989).
12. Haller H., C. Christel, L. Dannenberg, P. Thiele, F.C. Luft: Signal transduction of erythropoietin in endothelial cells. Kidney Int. 50, 481-488 (1996).
13. Hand M.F., W.G. Haynes, H.A. Johnstone, J.L. Anderton, D.J. Webb: Erythropoietin enhances vascular responsivness to norepinephrine in renal failure. Kidney Int. 48, 806-813 (1995).
14. Ishimitsu T., H. Tuskada, Y. Ogawa, A. Numabe, S. Yagi: Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am. J. Med. 94, 401-406 (1993).
15. Jabs K., W.E. Harmon: Recombinant human erythropoietin therapy in children on dialysis. Adv. Renal Replace Ther. 3, 24-36 (1996).
16. Kuriyama S., L. Hopp, H. Yoshida, M. Hikita, H. Tomonari, T. Hashimoto, O. Sakai: Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am. J. Hypertens. 9, 426-431 (1996).
17. Levin A., J. Singer, C.R. Thompson, H. Ross, M. Lewis: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am. J. Kidney Dis. 27, 347-354 (1996).
18. Martinez-Vea A., A. Bardaji, C. Garcia, C. Ridao, C. Richart, J.A. Oliver: Lon-gterm myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am. J. Kidney Dis. 19, 353-357 (1992).
19. Raine A.E., S.D. Roger: Effects of erythropoietin on blood pressure. Am. J. Kidney Dis. 18 (Suppl. 1), 76-83 (1991).
20. Roth D., R.D. Smith, G. Schulman: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am. J. Kidney Dis. 24, 777-784 (1994).
21. Sawka M.N., M.J. Joyner, R.J. Robertson, L.L. Spriet, A.J. Young: The use of blood doping as an ergogenic aid. Med. Sci. Sports Exerc. 28, 1-8 (1996).
22. Suga M., S. Kurihara, A. Terashi: Acute effects of human recombinant erythropoietin on cardiovascular dynamics and vasoactive substances. Nippon Jinzo Gakkai Shi 38, 634-639 (1996).
23. Sundal E., U. Kaeser: Correction of anemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicenter study of 150 hemodialysis-dependent patients. Nephrol. Dial. Transplant. 4, 979-987 (1989).
24. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am. J. Kidney Dis. 18, 50-59 (1991).
25. Vaziri N.D., X.J. Zhou, F. Naqvi, J. Smith, F. Oveisi, Z.Q. Wang, R.E. Purdy: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am. J. Physiol. 271, E113-E122 (1996).
26. Watson A.J., L.F. Gimenez, S. Cotton, M. Walser, J.L. Spivak: Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am. J. Med. 89, 432-435 (1990).
27. Zhou X.J., D. Pandian, X.Q. Wang, D. Vaziri: Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrialnatriuretic peptide levels. J. Am. Soc. Nephrol. 8, 901-905 (1997).